[HTML][HTML] The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
Abstract Chronic Myeloid Leukemia (CML) is characterized by chromosomal aberrations
involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a …
involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a …
[HTML][HTML] Telomere biology: from disorders to hematological diseases
K Roka, EE Solomou, A Kattamis - Frontiers in Oncology, 2023 - frontiersin.org
Variations in the length of telomeres and pathogenic variants involved in telomere length
maintenance have been correlated with several human diseases. Recent breakthroughs in …
maintenance have been correlated with several human diseases. Recent breakthroughs in …
c‐myb is involved in CML progression and is a therapeutic target in the zebrafish CML model
Y Ye, X Yang, F Li, W Liu, W Zhang… - Animal Models and …, 2024 - Wiley Online Library
Background Despite the success of tyrosine kinase inhibitors in chronic myeloid leukemia
(CML) therapy, CML still faces the challenges of drug resistance and progression to blast …
(CML) therapy, CML still faces the challenges of drug resistance and progression to blast …
[HTML][HTML] A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia
M Chen, X Fang, R Du, J Meng, J Liu, M Liu, Y Yang… - Pharmaceutics, 2023 - mdpi.com
Chronic myeloid leukemia (CML) is recognized as a classic clonal myeloproliferative
disorder. Given the limited treatment options for CML patients in the accelerated phase (AP) …
disorder. Given the limited treatment options for CML patients in the accelerated phase (AP) …
[HTML][HTML] Clinical Validation of the Somatic FANCD2 Mutation (c. 2022-5C> T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid …
Background: Chronic myeloid leukemia (CML) results from chromosomal translocation t (9;
22) leading to the formation of the BCR-ABL fusion oncogene. CML has three stages: the …
22) leading to the formation of the BCR-ABL fusion oncogene. CML has three stages: the …
Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML …
N Alanazi, A AlGarni, S Almukhaylid, M AlMajed… - medRxiv, 2024 - medrxiv.org
Background: Chronic Myeloid Leukemia (CML) is a myeloproliferative stem cell malignancy.
Chronic Phase CML (CP) is treatable with overall survival equivalent to general public …
Chronic Phase CML (CP) is treatable with overall survival equivalent to general public …
Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in …
Background: Chronic Myeloid Leukemia (CML) is initiated in the bone marrow due to the
chromosomal translocation t (9; 22), resulting in the fusion oncogene BCR-ABL. Tyrosine …
chromosomal translocation t (9; 22), resulting in the fusion oncogene BCR-ABL. Tyrosine …
Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CML
Background: Chronic Myeloid Leukemia (CML) is initiated in the bone marrow due to the
chromosomal translocation t (9; 22), resulting in the fusion oncogene BCR-ABL. Tyrosine …
chromosomal translocation t (9; 22), resulting in the fusion oncogene BCR-ABL. Tyrosine …
[HTML][HTML] CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL …
Background: Chronic Myeloid Leukemia (CML) is initiated in the bone marrow due to the
chromosomal translocation t (9; 22), resulting in the fusion oncogene BCR-ABL. Tyrosine …
chromosomal translocation t (9; 22), resulting in the fusion oncogene BCR-ABL. Tyrosine …
Blastický zvrat chronické myeloidní leukemie.
N Čuřík, A Láznička - Transfusiology & Haematology Today …, 2023 - search.ebscohost.com
Chronic myeloid leukaemia represents a model disease where the identification of driving
molecular mechanisms and their targeted therapy has led to dramatic improvement in …
molecular mechanisms and their targeted therapy has led to dramatic improvement in …